Biogen Inc. BIIB
Rating
Rating Factors
Company Overview
Biogen Inc. is a global biotechnology company focused on the discovery, development, manufacturing, and commercialization of therapies for neurological, neurodegenerative, and rare diseases. The company operates within the biopharmaceutical and life sciences industries, with a primary emphasis on neuroscience. Its core revenue is driven by disease-modifying treatments for multiple sclerosis (MS), spinal muscular atrophy (SMA), and emerging therapies for Alzheimer’s disease and other neurodegenerative conditions.
Founded in 1978 as Biogen N.V., the company was established by a group of leading scientists and has evolved through decades of scientific innovation and strategic acquisitions. Biogen has historically held a strong competitive position in MS therapies and has leveraged this foundation to expand into broader neuroscience and rare disease markets. Its strategy emphasizes high unmet medical needs, biologics expertise, and long-term investment in advanced research and clinical development.
Income Statement
Balance Sheet
Cash Flow
Filings
Price History
- Low
- $138.00
- Current
- $219.88
- High
- $230.49
Valuation
Dividends and Shares
Corporate Info
Cambridge, MA 02142